By: Benzinga
Isis Pharmaceuticals to Provide Update on FDA Approval of KYNAMRO, 09:30 AM ET, Wednesday, January 30, 2013
Isis Pharmaceuticals (NASDAQ: ISIS ) announced today that it will conduct a conference call and webcast to provide an update on the U.S. Food and Drug Administration (FDA) approval of the marketing of KYNAMRO™ (mipomersen) for the treatment of patients with Homozygous Familial Hypercholesterolemia (HoFH). CONFERENCE CALL At 09:30
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here